Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efficacy of NSAIDs in BPH
NCT00687388Phase 4Withdrawn
- Sponsor
- Samsung Medical Center
- Start
- May 2008
- Primary completion
- Mar 2012
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of celecoxib in benign prostatic hyperplasia (BPH) (3 arms), sponsored by Samsung Medical Center. Primary endpoint: International Prostatic Symptom Score at 8 weeks. Planned start May 2008; status: withdrawn.
02
Drugs
celecoxib
03
Conditions
benign prostatic hyperplasia (BPH)
Beyond the preview
Go deeper on NCT00687388.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00687388.